10x Genomics Reports Lower Quarterly Loss
10x Genomics, Inc. (NASDAQ: TXG) has recently revealed its third-quarter financial results. The company faced a quarterly loss of 30 cents per share, which is an improvement compared to market anticipations that estimated a larger loss of 34 cents per share. However, the company reported sales of $151.654 million, which fell short of analyst consensus expectations that were set at $158.632 million.
Challenges Impacting Financial Performance
Serge Saxonov, Co-founder and CEO of 10x Genomics, expressed that the results did not align with expectations, citing significant disruptions caused by a sales restructuring initiated during the quarter alongside cautious customer spending. "These dynamics are particularly felt amid a challenging macroeconomic environment, impacting our revenue growth forecasts for the year," Saxonov stated. He remained optimistic that the strategies being implemented would expand their customer reach and enhance their service delivery across the product portfolio.
Revised Revenue Guidance for FY24
In light of the current challenges, 10x Genomics has revised its revenue guidance for the fiscal year 2024. The new expectations range from $595 million to $605 million, down from the previously anticipated range of $640 million to $660 million.
Market Reaction and Stock Performance
Following the earnings report, 10x Genomics shares experienced a modest increase of 6.3%, settling at $16.79. This fluctuation in stock price reflects the market's response to the company's quarterly performance and future outlook.
Analysts Adjust Price Targets
In reaction to the recent quarterly results, several analysts have made adjustments to their price targets for 10x Genomics:
UBS Analyst Assessment
UBS analyst Dan Leonard reaffirmed a Neutral rating on 10x Genomics’ stock but reduced the price target from $25 to $20, signaling cautious optimism.
JP Morgan's Outlook
Similarly, JP Morgan analyst Rachel Vatnsdal also maintained a Neutral rating, but slashed the price target from $20 down to $14, indicating potential concerns regarding the company's growth trajectory.
Goldman Sachs' Position
Matthew Sykes from Goldman Sachs has adopted a Sell rating on the stock. He lowered the price target from $16 to $14, reflecting significant doubts regarding 10x Genomics’ near-term prospects.
Citigroup’s Rating
In contrast, Citigroup analyst Patrick Donnelly maintained a Buy rating on the stock while decreasing the price target from $35 to $23, suggesting that there could still be considerable long-term value in the company.
Investor Considerations for TXG Stock
As investors contemplate whether to consider purchasing TXG stock, the differing opinions from analysts may provide varied insights. The mixed ratings and adjustments reveal underlying uncertainties about the company’s performance in the upcoming quarters, as well as the potential implications of the current market dynamics.
Frequently Asked Questions
What were 10x Genomics' earnings per share in Q3?
The company reported a quarterly loss of 30 cents per share for the third quarter.
How did 10x Genomics' sales compare to expectations?
They reported sales of $151.654 million, which was below the analyst consensus estimate of $158.632 million.
What is the new revenue guidance for FY24?
10x Genomics revised its FY24 revenue guidance to between $595 million and $605 million.
What was the response of 10x Genomics' stock after the earnings report?
The stock gained 6.3%, trading at $16.79.
What are analysts' new price targets for TXG?
Analysts have adjusted their price targets to between $14 and $23, reflecting a range of outlooks on the stock's future performance.
